慢性淋巴细胞白血病
医学
淋巴瘤
滤泡性淋巴瘤
耐火材料(行星科学)
白血病
内科学
肿瘤科
药品
癌症研究
药理学
生物
天体生物学
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2018-12-01
卷期号:8 (12): OF4-OF4
被引量:4
标识
DOI:10.1158/2159-8290.cd-nb2018-137
摘要
Abstract The FDA approved duvelisib, a PI3Kδ/PI3Kγ inhibitor, for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least two prior therapies. The agency also granted the drug an accelerated approval for patients with relapsed/refractory follicular lymphoma following at least two other therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI